Akorn Recalls COSOPT Ophthalmic Solution Due to Stability Failures
Akorn Inc. is recalling 30,794 bottles of COSOPT Ophthalmic Solution because the product failed stability specifications for opalescence.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor specification issues.
Plain-English summary
Akorn Inc. is recalling 30,794 bottles of COSOPT Ophthalmic Solution, USP (2% Dorzolamide Hydrochloride, 0.5% Timolol Maleate), 10 mL dropper bottle. The recall involves lots 426007 and 426008 with an expiration date of 4/2020. The product is distributed nationwide in the United States and Puerto Rico.
The recall was initiated because the product failed stability specifications, specifically showing out-of-specification results for opalescence during a 7-month stability study. The U.S. Food and Drug Administration has classified this as a Class III recall.
Consumers should stop using the affected product and contact their healthcare provider or pharmacist for guidance on replacement or disposal. The recalled product is identified by NDC 17478-605-10.
The recalled product
- Product
- COSOPT Ophthalmic Solution, USP, (2% Dorzolamide Hydrochloride, 0.5% Timolol Maleate), 10 mL dropper bottle, Sterile, Rx only, Distributed by: Akorn, Inc., Lake Forest, IL, NDC: 17478-605-10
- Manufacturer
- Akorn Inc
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 30,794
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: 426007 and 426008
- exp 4/2020
Distribution
Related recalls
Same manufacturer · Akorn Inc
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24